Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2019 ASH Annual Meeting
Oncology Conference Multimedia
View more videos >>
OncLive News Network On Location: ASH 2019 Day 3
Dr. Brown on Blinatumomab Versus Chemotherapy as Post-Reinduction Therapy in B-ALL
Identification of Prognostic Constellations of Driver Mutations in AML and MDS
Oncology Conference Articles
Brentuximab Vedotin Demonstrates Durable Long-Term PFS Benefit in Hodgkin Lymphoma
The addition of brentuximab vedotin to standard 3-drug chemotherapy for patients with newly diagnosed, advanced-stage classical Hodgkin lymphoma continued to outperform a 4-drug chemotherapy standard.
ADC Targeting CD123 Active in R/R AML and BPDCN
IMGN632, an investigational anti-CD123 antibody-drug conjugate, demonstrated preliminary activity in patients with relapsed/refractory acute myelogenous leukemia or blastic plasmacytoid dendritic cell neoplasm.
Resistance-Targeting BTK Inhibitor ARQ 531 Active Across B-Cell Malignancies
The investigational Bruton tyrosine kinase inhibitor ARQ 531 demonstrated safety and clinical activity across a range of B-cell malignancies.
Large PFS Gain With Daratumumab in Transplant-Ineligible Myeloma
More than three times as many patients with transplant-ineligible newly diagnosed multiple myeloma remained alive and progression free after >3 years when they received daratumumab (Darzalex) in addition to standard first-line therapy.
Updated bb21217 Data Continue to Impress in Multiple Myeloma
The CAR T cell therapy bb21217 demonstrated high very good partial response or better rates in patients with heavily pretreated relapsed/refractory multiple myeloma.
Luspatercept Reduces Transfusion Burden in Transfusion-Dependent Patients With Beta-Thalassemia
A majority of adult patients with β-thalassemia who require regular red blood cell transfusions experienced clinically meaningful and durable transfusion burden reduction associated with luspatercept (Reblozyl).
Bispecific Antibody Shows High Clinical Activity in Heavily Pretreated NHL
REGN1979 demonstrated antitumor activity with an acceptable safety profile in heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Addition of BET Inhibitor to Ruxolitinib Reduces Spleen Volume, Improves Symptoms in Myelofibrosis
The addition of CP-0610 to ruxolitinib (Jakafi) in JAK inhibitor-naïve patients with myelofibrosis induced splenic and symptomatic responses as early as 12 weeks.
Tisagenlecleucel Demonstrates Real-World Clinical Benefit in DLBCL
The CAR T-cell therapy tisagenlecleucel (Kymriah) showed similar real-world efficacy and safety findings to that of the JULIET trial in the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma.
Daratumumab Boosts Outcomes in Transplant-Eligible Myeloma
Adding an anti-CD38 antibody to a 3-drug chemotherapy-free regimen led to deeper and more frequent responses in patients with transplant-eligible, newly diagnosed multiple myeloma.
Navitoclax Overcomes Ruxolitinib Resistance for Myelofibrosis
Navitoclax plus ruxolitinib (Jakafi) showed clinically meaningful spleen responses and improvements in symptoms for patients with primary or secondary myelofibrosis, following the development of resistance to frontline ruxolitinib.
Daratumumab Plus Carfilzomib and Dexamethasone Extends PFS in Relapsed/Refractory Myeloma
Adding daratumumab (Darzalex) to carfilzomib (Kyprolis) and dexamethasone reduced the risk of disease progression or death by 37% compared with carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Maintenance CC-486 Improves Survival for Older Patients With AML
Maintenance treatment with CC-486, an oral formulation of azacitidine, extended median overall survival by 9.9 months compared with placebo for older patients with acute myeloid leukemia in first remission.
Blinatumomab as Post-Reinduction Therapy Improves Survival in Pediatric and AYA B-ALL
Blinatumomab (Blincyto) as post-reinduction consolidation therapy before hematopoietic stem cell transplantation improved disease-free survival and overall survival by approximately 20% compared with intensive chemotherapy in pediatric and adolescent and young adult patients with high- or intermediate-risk of first relapse of B-cell acute lymphoblastic leukemia.
Enasidenib Plus Azacitidine Significantly Improves Responses in Newly Diagnosed
Enasidenib significantly improves complete remission and overall response when combined with azacitidine compared with azacitidine alone in patients with newly diagnosed acute myeloid leukemia with
KTE-X19 Shows High CR Rates for MCL, FDA Submission Planned
Treatment with the anti-CD19 CAR T-cell therapy KTE-X19 elicited a complete remission rate of 67% and an objective response rate of 93% for patients with relapsed/refractory mantle cell lymphoma.
Acalabrutinib Benefit in CLL Sustained With Long-Term Follow-Up
Patients with relapsed/refractory chronic lymphocytic leukemia had ongoing benefits 42 months after starting treatment with the BTK inhibitor acalabrutinib.
CPI-0610 Shows Strong Efficacy Signals for Advanced Myelofibrosis
CPI-0610 showed promising spleen volume responses and a meaningful reduction in total symptom score as monotherapy and in combination with ruxolitinib (Jakafi) for patients with refractory or intolerant advanced myelofibrosis.
Patients with B-Cell Malignancies Experience Stable Disease on Vecabrutinib Therapy
Vecabrutinib, a reversible, noncovalent Bruton’s tyrosine kinase inhibitor, exhibited evidence of clinical activity in adults with B-cell malignancies without producing any grade ≥3 treatment-related adverse events.
Liso-Cel Continues to Show Promise in Relapsed/Refractory CLL/SLL
The CD19-directed CAR T-cell therapy lisocabtagene maraleucel showed promising clinical activity and manageable toxicity in heavily pretreated patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma, all of whom had progressed on ibrutinib.
Initial Higher-Dose Duvelisib Improves Responses in Relapsed/Refractory PTCL
Patients with relapsed/refractory peripheral T-cell lymphoma who received a higher initial dose of duvelisib at 75 mg BID had a higher overall response rate of 62% than those who received 25 mg BID.
Zanubrutinib Effective in CLL/SLL, Regardless of Del(17p) Status
The BTK inhibitor zanubrutinib continues to demonstrate high overall response rates for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, regardless of the presence of high-risk cytogenetics.
LOXO-305 Is Highly Effective in Heavily Pretreated B-cell Malignancies
More than half of patients with heavily pretreated B-cell malignancies responded to the noncovalent BTK inhibitor LOXO-305, including those with resistance or intolerance to other BTK inhibitors or BCL2 inhibitors.
Early Steroid Use Reduces Risk of Cytokine Release Syndrome With Axi-Cel
Steroid use while cytokine release syndrome and neurologic toxicities are at grade 1, instead of waiting until grade 3, reduces the rate of CAR T-cell treatment–related CRS and neurologic events.
Lenalidomide Plus Obinutuzumab Achieves 100% ORR in Rituximab-Refractory Indolent Non-Hodgkin Lymphoma
The combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) elicited a 100% overall response rate in patients with relapsed indolent non-Hodgkin lymphoma that was refractory to rituximab (Rituxan).
Lenalidomide/Rituximab PFS Benefit Maintained in Elderly Subgroup With Indolent Non-Hodgkin Lymphoma
The combination of lenalidomide (Revlimid) and rituximab showed a 34% reduction in the risk of disease progression or death compared with rituximab plus placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma, although it was not found to be statistically significant.
Ibrutinib May Thwart PFS Decline in R/R Mantle Cell Lymphoma
In patients with relapsed mantle cell lymphoma, treatment with ibrutinib might mitigate a historical trend toward decreased progression-free survival with succeeding lines of therapy.
Liso-Cel Induces High Rate of Durable Responses in LBCL
CD19-directed CAR T-cell therapy induced a high rate of rapid and durable complete responses in patients with aggressive relapsed/refractory large B-cell lymphoma.
Novel Triplet Shows Early Promise for Pretreated CLL
The triplet of umbralisib, ublituximab, and venetoclax induced a complete remission rate of 44% as a treatment for patients with relapsed/refractory chronic lymphocytic leukemia.
Triplet Regimen Induces High Rate of CR in R/R Follicular Lymphoma
The combination of polatuzumab-vedotin (Polivy), obinutuzumab (Gazyva), and lenalidomide (Revlimid) induced a high rate of durable responses in patients with relapsed/refractory follicular lymphoma.
Acalabrutinib Triplet Highly Active in Frontline CLL
The triplet of acalabrutinib (Calquence), venetoclax (Venclexta), and obinutuzumab (Gazyva; AVO) is highly active as frontline therapy for patients with chronic lymphocytic leukemia.
Ibrutinib/Rituximab Combo Retains PFS Advantage Over FCR in CLL
With extended follow-up, progression-free survival continues to be superior with the combination of ibrutinib and rituximab compared with fludarabine, cyclophosphamide, and rituximab for patients ≤70 years with previously untreated chronic lymphocytic leukemia.
Frontline Ibrutinib/Venetoclax Combo Leads to High Rates of Undetectable MRD in CLL
The first-line combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) led to a 75% undetectable minimal residual disease rate in peripheral blood and 72% in bone marrow in patients with chronic lymphocytic leukemia.
Axi-Cel Elicits 47% 3-Year OS Rate in B-Cell Lymphoma
The CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) induced a median overall survival of 25.8 months for patients with refractory large B-cell lymphoma.
Anti-BCMA CAR-T JNJ-4528 Hits 100% Response Rate in Heavily Pretreated Myeloma
The BCMA-directed CAR T-cell therapy JNJ-4528 achieved a 100% overall response rate with early and deep responses in 29 patients with heavily pretreated relapsed/refractory myeloma.
Novel Antibody Elicits Complete Remissions in NHL After CAR Relapses
Mosunetuzumab, a novel bispecific antibody, generated durable responses in patients with highly refractory non-Hodgkin lymphomas, including complete remissions in 22.2% of those who had previously received chimeric antigen receptor T-cell therapy.
Extramedullary Multiple Myeloma Responds to Dual-Targeting CAR T-Cell Therapy
Chimeric antigen receptor T-cell therapy targeting both BCMA and CD38 induced an objective response in >90% of patients with multiple myeloma who had been treated with at least 3 prior therapies and whose disease had spread outside of the bone marrow.
Acalabrutinib Alone or in Combination Improves PFS in Frontline CLL
Acalabrutinib (Calquence) as a single agent or in combination with obinutuzumab (Gazyva) significantly improved progression-free survival compared with obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia.
Anti-BCMA, CD3 Agent CC-93269 Shows Promise for Heavily Pretreated Myeloma
CC-93269 showed encouraging signs of dose-dependent efficacy with a safety profile that continues to be refined for patients with heavily pretreated relapsed/refractory multiple myeloma.
Fate Touts Novel Off-the-Shelf Cell Therapy
An investigational new drug application for the therapy, which is labeled FT596, was approved in September 2019 and human trials are scheduled to begin in the first quarter of 2020.
Landgren Previews Pivotal ASH 2019 Myeloma Data
Ahead of the 2019 ASH Annual Meeting, C. Ola Landgren, MD, PhD, shares insight on the potentially practice-changing data in the multiple myeloma paradigm that will be discussed at the conference.
Challenges in Treating Relapsed/Refractory Multiple Myeloma
Relapsed/refractory multiple myeloma continuously develops resistance to treatment, which means the therapeutic paradigm must also continue to shift. While treatment failure remains a major barrier, there is hope on the horizon.
ASCO GU 2020: Dr. Taplin Highlights Ongoing Research in Prostate Cancer
Dr. Garcia on Efficacy of Navitoclax in Ruxolitinib-Resistant Myelofibrosis
Real-World Evidence Should Be Part of Clinical Trials in Oncology
Community Oncologist Discusses CAR T-Cell Therapy and Other Hematology Advances
Biosimilars in Cancer Care: Potentially Improving Patient Access to Essential Therapies
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.